Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Drug Manufacturers - Specialty & Generic

Healthcare
$1.50 +1047.56%

+$7.31 today

Market cap
$71.09M
Beta
-2.17
P/E (TTM)
-36.3
EPS (TTM)
-$1.50
52W Low $0.62High $13.08

Volume 0.02M

Average 0.10M

ZYBT Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT

Capital Expenditures · Q4 FY2025 · quarter ended Dec 2025

Capital expenditures of -CN¥743.56K in Q4 FY2025

Q4 FY2025 capital expenditures was -CN¥743.56K. Over 3 fiscal years it compounded at -22.7% a year.

Context

  • Capital expenditures amounted to 10.9% of revenue in FY2025, down 4.0 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-CN¥743.56K+97.5% QoQ
Last fiscal yearDec 2025
-CN¥12.63M-54.5% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-54.5%——
3-year CAGR-22.7%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

CNY · from the cash flow

Latest · FY2025
(12.63M) CNY
Year-over-year change
+54.5%

Capital Expenditures vs competitors

How ZYBT compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -54.5% is the 6th highest of 8, against a peer median of +50.8%.
  • Capital expenditures amounts to 10.9% of revenue for ZYBT, versus a peer median of 2.5%.
ZYBT Competitors
Capital Expenditures for ZYBT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYBTZhengye Biotechnology Holding LimitedFY2025CN¥12.63M CNY-54.5%-22.7%10.9%
APYXApyx Medical CorporationLTM Mar 2026$1.12M USD+50.8%+3.3%2.0%
SERASera Prognostics, Inc.LTM Mar 2026$731K USD+86.5%-2.8%1282.5%
PDEXPro-Dex, Inc.LTM Mar 2026$373K USD-70.4%-9.3%0.5%
SRZNSurrozen, Inc.LTM Mar 2026$221K USD+380.4%-44.0%2.9%
EXOZeXoZymes, Inc.LTM Mar 2026$196.47K USD-29.5%-3.0%—
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$60.26K CAD+102.4%-31.1%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$15.65K CAD-91.9%-46.9%—
TILInstil Bio, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ZYBT) —+50.8%-9.3%2.5%

Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income46.47M55.74M37.51M13.47M(82.97M)
Depreciation & Amortization16.01M18.8M23.91M24.16M25.96M
Deferred Income Tax(358K)(1.09M)758K924K11.1M
Stock-Based Compensation00000
Change in Working Capital(33.71M)(66.82M)(20.49M)(977K)44.83M
Accounts Receivables(40.91M)(47.38M)38.05M11.31M61.41M
Inventory(12.34M)(12.33M)(12.9M)(5.88M)6.25M
Accounts Payables17.63M(9.67M)(35.61M)(404K)(3.36M)
Other Working Capital1.91M2.56M(10.03M)(6M)(19.47M)
Other Non-Cash Items3.4M10.7M6.5M3.47M14.42M
Operating Cash Flow31.81M17.34M48.18M41.05M13.33M
Capital Expenditures(26.4M)(27.33M)(11.6M)(27.77M)(12.63M)
Acquisitions (Net)00000
Purchases of Investments00(1.22M)00
Sales of Investments00000
Other Investing Activities(7.21M)0(3.15M)(14.08M)(11.62M)
Investing Cash Flow(26.27M)(27.33M)(11.77M)(27.67M)(12.63M)
Debt Repayment8M34.88M24.97M(2.74M)(12.09M)
Common Stock Issued000043.08M
Common Stock Repurchased00000
Dividends Paid(11.05M)(21.43M)(39.45M)(16.02M)0
Other Financing Activities0(1)(4.5M)(3.37M)1.32M
Financing Cash Flow(3.05M)13.46M(18.98M)(22.13M)32.31M
Effect of Forex Changes000168K(1.29M)
Net Change in Cash2.49M3.46M17.44M(8.58M)31.73M
Free Cash Flow5.41M(9.99M)36.58M13.27M703K

Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Intrinsic Alpha fair value

Locked

Current Price

$1.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.